MY ACCOUNT | NEWSLETTER |

Thyroidectomy in dogs with thyroid tumors: survival analysis in 144 cases


The objective of this study was to estimate the survival and identify prognostic factors in dogs with thyroid tumors treated by thyroidectomy.

Thyroid tumors in dogs have a prevalence of 1-4% among all neoplasms and represent the most common tumor of the neuroendocrine system. Older dogs are affected more frequently, and the beagle, boxer and golden retriever breeds are overrepresented.

Carcinomas are the most frequent thyroid tumors in dogs and, among them, 70% arise from follicular cells (i.e, follicular thyroid carcinomas) and 30% from parafollicular cells (i.e., medullary thyroid carcinomas), both are invasive. Adenomas, on the other hand, are rare in dogs. In dogs, follicular thyroid carcinomas are histologically classified as well-differentiated (i.e., follicular, compact, follicular-compact and papillary), poorly differentiated, undifferentiated and carcinosarcoma (malignant mixed thyroid tumor).

Researchers included a total of 144 client-owned dogs with thyroid neoplasia that underwent thyroidectomy in the retrospective study. Data for analysis included hospital attended and year of surgery, signalment, thyroxine concentration, thyroid tumor features — lobe involvement, size, invasiveness, histopathological type — thrombosis, metastasis, additional surgery and therapy, administration of adjuvant chemotherapy. 

The association of predictors with survival, time from surgery to death, were assessed by calculating cause-specific hazard ratios (HRs) and 95% confidence intervals (CI). Causes of death were classified as thyroid-related or because of other cause.

Overall median survival time was 802 days (CI95% = 723-1015 days). In addition, 

  • 89 dogs (77.4%) survived >500 days.
  • Metastases were identified by the team at admission in 12 (8.3%) dogs and were associated with higher thyroid cancer-related fatality (HR = 5.83, CI95% = 1.56-21.78; P = .009).
  • Thrombosis occurred in 40 dogs and was associated with increased risk of death because of other cause (HR = 2.73, CI95% = 1.18-6.35; P = .019).
  • Nonfollicular carcinoma (HR = 4.17, CI95% = 1.27-13.69; P = .018) and administration of chemotherapy (HR = 3.45, CI95% = 1.35-8.82; P = .01) were associated with higher risk of thyroid cancer-related death.

In conclusion, the authors said that dogs with thyroid tumors undergoing thyroidectomy have a long life expectancy. Despite the rare presence of nonfollicular carcinoma and metastases, thyroidectomy should still be considered in some of these dogs.

Daniela Enache, et al. “Thyroidectomy in dogs with thyroid tumors: Survival analysis in 144 cases (1994-2018).” J Vet Intern Med. 2023 Feb 27. doi: 10.1111/jvim.16644.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Feline injection site sarcomas

Like0
Dislike0

C-reactive protein concentrations in canine acute pancreatitis

Like0
Dislike0

A retrospective clinical investigation of the safety and adverse effects of pantoprazole in hospitalized ruminants

Like0
Dislike0

Dr. Marjorie Bercier Publishes Study on Novel Diagnostic Approach for Prevalent Elephant Virus

Like0
Dislike0

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top